Items tagged with Treatment
Alpibectir-ethionamide safe for TB, with similar activity to isoniazid (post)
DENVER, March 7, 2024 -- In patients with tuberculosis (TB), a novel fixed-dose combination of alpibectir-ethionamide had similar levels of bactericidal activity as isoniazid, with no serious adverse events and good tolerability, a phase II randomized controlled trial showed.
Gilead press release: Biktarvy® demonstrates high rates of viral suppression in people with HIV and comorbidities (post)
March 06, 2024: Gilead Sciences, Inc. announced new data from three studies evaluating the efficacy and safety profile of Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) for a broad range of people with HIV, including those with HIV/hepatitis B (HBV) coinfection and HIV/tuberculosis (TB) coinfection. These data and other studies supporting the important role of Biktarvy in the HIV treatment landscape were presented at the 31st Conference on Retroviruses and Opportunistic Infections (CROI).
Comparative analysis of TB preventive therapy efficacies in HIV patients (post)
Latent Tuberculosis Infection (LTBI) is associated with increased immune activation and a heightened risk of cardiovascular diseases. The ACTG A5279 trial, a phase 3 study presented at the Conference on Retroviruses and Opportunistic Infections (CROI), investigated the activation patterns of monocytes in individuals with HIV (PWH). This trial compared the efficacy of 4 weeks of daily rifapentine (RFP) and isoniazid (INH) against 9 months of daily INH for Tuberculosis Preventive Therapy (TPT). At baseline and week 48, PWH with LTBI, compared to those with negative TST/IGRA results, demonstrated changes in monocytes indicative of ongoing activation and tissue migration.
CROI 2024 TB research round up (post)
Treatment Action Group (TAG) released an overview of TB research data reported at the 31st Conference on Retroviruses and Opportunistic Infections (CROI 2024) held on 3-6 March 2024 in Denver, Colorado, USA.
Radiant Moms online survey (post)
Radiant Moms is a study that aims to explore the feasibility, acceptability, and perceived demand for the new 17-week RPT-MOX regimen (rifapentine, moxifloxacin, isoniazid and pyrazinamide) for pregnant and breastfeeding women among key stakeholders. The study has been approved by the Columbia University Irving Medical Center Institutional Review Board in the U.S. and the Stellenbosch University Research Ethics Committee in South Africa, as a collaborative project.
Brazil: Isoniazid resistance linked with TB deaths (post)
In 2022, more than 78,000 new cases of tuberculosis (TB) were reported in Brazil, with an incidence of 36.3 cases per 100,000 inhabitants. According to researchers from the Regional Prospective Observational Research for Tuberculosis (RePORT)-Brazil consortium, the country could improve the control of this infection if all patients were subjected to a sensitivity test capable of early detection of resistance not only to rifampicin, but also to isoniazid, before starting treatment. A study by the consortium published this year in Open Forum Infectious Diseases found that monoresistance to isoniazid predicted unfavorable outcomes at the national level.
WHO announces forthcoming updates on co-administration of treatment for drug-resistant TB and hepatitis C (post)
9 April 2024 — In a Rapid Communication issued today, the World Health Organization (WHO) is announcing updates on co-administration of treatment for drug-resistant tuberculosis and hepatitis C (HCV). The evidence suggests that concomitant treatment for HCV and multidrug-resistant or rifampicin-resistant TB (MDR/RR-TB) is feasible, with potential benefits outweighing the harms. Co-administration may increase MDR/RR-TB treatment success and reduce failures, losses to follow-up, and deaths. Adherence support for HCV treatment during MDR/RR-TB treatment is also acknowledged.
1/4/6x24 Mid-campaign report launch webinar - recording now available online (post)
The 1/4/6x24 Campaign and the Stop TB Partnership co-hosted a webinar on 27 March 2024 to launch the Campaign’s new report: Getting Better Faster: Delivering on the Promise of New TB Treatments. The report highlights progress and gaps in scaling up access to shorter, safer TB regimens — one month or once weekly for TB prevention, four months for drug-susceptible TB, and six months for drug-resistant TB — by the end of 2024.
Rifampicin flat dosing and weight-banded dosing comparable in patients with TB (post)
The flat-dose vs weight-banded-dose cohorts did not differ with respect to TB-related unfavorable outcomes at 9, 12, and 18 months after treatment initiation.
WHO BPaLM Accelerator Platform (post)
The WHO BPaLM Accelerator Platform was established in January 2023, right after the update of the World Health Organization (WHO) guidelines on the treatment of drug-resistant TB in 2022. The purpose of the WHO BPaLM Accelerator Platform is to support countries and stakeholders in information exchange and technical discussions to address challenges in the adoption and implementation of the BPaLM/BPaL regimen (consisting of bedaquiline, pretomanid, linezolid and moxifloxacin, with the provision of dropping moxifloxacin in case of confirmed resistance to fluoroquinolones). This is also to support the Call to Action on rolling out of the BPaLM regimen and other short regimens for treatment of drug-resistant TB that was initiated by WHO and its multiple partners.
Page 74 of 108 · Total posts: 0
←First 73 74 75 Last→